These results, together with previous evidence using genetic ablation of PDPK1, provide a strong rationale to investigate further the use of PDK1 inhibitors in PDAC as novel therapeutic strategies for pancreatic cancer patients. This evidence concerns the gene PDK1 and pancreatic neoplasm.